In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Data And Connected Insight Will Take Corin Beyond COVID-19

Private UK Implants Company Has Its Own Take On Innovation That Creates Health Care Value

Executive Summary

Corin has transformed from a niche UK hip resurfacing company into an innovative global player in orthopedics with a portfolio that includes robotics. UK branch managing director Paul Gibbons explained the group’s approach to business during COVID-19 and its culture of innovation.

You may also be interested in...



COVID-19: UK NHS Chief Calls For 90% Return To Planned Care Within 3 Months

The much-anticipated return to a “normal” NHS service delivery could yet be dashed by a resurgence of the virus.

Just Three UK Medical Device Notified Bodies Left As LRQA Pulls Out

Medtech companies that have been loyal to LRQA could find themselves at a serious competitive disadvantage as the organization pulls out as a notified body for medical devices and IVDs, putting the whole medtech regulatory system under increased stress.

Patient-Specific Drive Takes Ortho Group Corin Into TKR Robotics With Omni Purchase

Hip and knee replacement firm Corin Group is taking its digitally-connected ecosystem concept a stage further after agreeing to acquire US-based Omni Orthopaedics Inc., a pioneer in robotic-assisted total knee replacement. The transaction will be completed in the first half of March.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV124602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel